Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01599832 · ClinicalTrials.gov registry record · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
A NA study, sponsored by University of Chicago.
- Terminated
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT01599832 is a NA study that was terminated before completion, run by University of Chicago. The registered enrollment target is 20 participants.
The verdict
NCT01599832, a NA study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects pazopanib (pazopanib hydrochloride) (also called Votrient®) may have on MRI (magnetic resonance imaging) scans, blood pressure, and various proteins in the blood. Pazopanib is Food and Drug Administration (FDA) approved for treating renal cell cancer. It is an agent that prevents angiogenesis, which is new blood vessel formation. The use of pazopanib described in this study is a standard of care, but the additional MRI and blood tests that will be performed are experimental
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacogenomic studies
- PROCEDURE dynamic contrast-enhanced magnetic resonance imaging
- DRUG pazopanib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01599832
The ClinicalTrials.gov registry entry for NCT01599832 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01599832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01599832 about?
NCT01599832 is a clinical study titled "Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer". The purpose of this study is to find out what effects pazopanib (pazopanib hydrochloride) (also called Votrient®) may have on MRI (magnetic resonance imaging) scans, blood pressure, and various proteins in the blood. Pazopanib is Food and Drug Administration (FDA) approved for treating renal cell ca...
What is the current status of trial NCT01599832?
This trial is currently terminated. It is a NA study. The enrollment target is 20 participants. The study started on 2012-06. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01599832?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacogenomic studies (OTHER), dynamic contrast-enhanced magnetic resonance imaging (PROCEDURE), pazopanib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01599832?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.